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Background/Aims: This study aimed to investigate whether the apolipoprotein 
(Apo) B/ApoA-I ratio is associated with carotid intima-media thickness (CIMT) in 
type 2 diabetes mellitus (T2DM) subjects with low density lipoprotein cholesterol 
(LDL-C) levels less than 100 mg/dL.
Methods: This cross-sectional study included 845 subjects aged with T2DM 40 
to 75 years who had visited Huh’s Diabetes Center in Seoul, Republic of Korea for 
CIMT measurement. Traditional fasting lipid profiles, ApoB and ApoA-I levels 
were examined. CIMT was measured at three points on the far wall of 1 cm long 
section of the common carotid artery in the proximity of the carotid bulb. The 
mean value of six measurements from right and left carotid arteries were used as 
the mean CIMT. In this study, carotid atherosclerosis was defined as having a fo-
cal plaque or diffuse thickening of the carotid wall (mean CIMT ≥ 1.0 mm) 
Results: The prevalence of carotid atherosclerosis increased with ApoB/ApoA-I ra-
tio. The ApoB/ApoA-I ratio, expressed as both quartiles (odds ratio [OR], 2.14; 95% 
confidence interval [CI], 1.21 to 3.79; p for trend = 0.014) and continuous values (OR, 
10.05; 95% CI, 3.26 to 30.97; p < 0.001), was significantly associated with a higher 
risk for carotid atherosclerosis, regardless of conventional cardiovascular disease 
risk factors. The optimal ApoB/ApoA-I ratio cutoff value for detecting carotid 
atherosclerosis was 0.57, based on receiver operating characteristic curve analysis 
with a sensitivity of 58.0% and a specificity of 55.1%. 
Conclusions: A high ApoB/ApoA-I ratio was significantly associated with carotid 
atherosclerosis in T2DM patients with LDL-C levels less than 100 mg/dL. 
Keywords: Apolipoprotein B/Apolipoprotein A-I ratio; Carotid intima-media 
thickness; Cholesterol, LDL; Diabetes mellitus, type 2 
ApoB/ApoA-I ratio is independently associated with 
carotid atherosclerosis in type 2 diabetes mellitus 
with well-controlled LDL cholesterol levels 
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INTRODUCTION
Low density lipoprotein cholesterol (LDL-C) is an inde-
pendent determinant of cardiovascular disease (CVD). 
The American Diabetes Association recommends that a 
moderate intensity statin should be considered for pa-
tients aged 40 to 75 years with diabetes, even when addi-
tional CVD risk factors are not present [1]. Several other 
guidelines also include LDL-C as a primary target for 
initial lipid-lowering treatment [2-4]. However, LDL-C 
levels are not always elevated in patients with coronary 
heart disease (CHD) [5,6]. One possible explanation for 
this is that specific LDL sub-fractions, rather than to-
tal LDL-C, may be more important in atherosclerosis 
because small dense LDL particles can easily penetrate 
into the arterial wall and are more susceptible to oxi-
dation [7]. In addition, substantial LDL-C heterogenicity 
was found in type 2 diabetes mellitus (T2DM) patients 
with LDL-C levels less than 100 mg/dL [8].
In addition to total cholesterol, different lipoprotein 
fractions can also inform CVD risk. A single molecule 
of apolipoprotein (Apo) B is present in each small dense 
LDL, and reflects the total number of atherogenic par-
ticles. In addition, ApoA-I transfers excess cholesterol 
to the liver from high density lipoprotein (HDL) parti-
cles [9]. Therefore, the ApoB/ApoA-I ratio is a marker 
of atherogenic and anti-atherogenic cholesterol balance 
in plasma [10,11]. Previous studies found that the ApoB/
ApoA-I ratio was significantly associated with the risk 
of fatal myocardial infarction (MI) regardless of conven-
tional CVD risk factors [12,13], even when the levels of 
other lipids were within normal ranges [14]. Moreover, 
one study found that the ApoB/ApoA-I ratio was a supe-
rior predictor of CHD risk compared to the total choles-
terol/HDL-C, LDL-C/HDL-C, and non HDL-C/HDL-C 
ratio [15]. 
Insulin resistance is related to abnormalities in plas-
ma lipid and lipoprotein levels. Diabetic dyslipidemia 
is characterized by hypertriglyceridemia, low HDL-C, a 
predominance of small dense LDL, and normal to high 
LDL-C levels [16]. Therefore, the aim of this study was to 
investigate whether the ApoB/ApoA-I ratio is associated 
with subclinical atherosclerosis, as assessed by carotid 
intima-media thickness (CIMT) in T2DM patients with 
well-controlled LDL-C levels. 
METHODS
Study subjects 
In total, 3,637 subjects with T2DM aged 40 to 75 years, 
who visited Huh’s Diabetes Center in Seoul, Republic of 
Korea from 2003 to 2008 and who had CIMT measure-
ments, were retrospectively screened. Of these patients, 
834 were excluded due to previous history of CVD (n = 
34), abnormal liver function tests such as elevated total 
bilirubin > 2.0 mg/dL or liver enzymes more than twice 
the upper normal limit (n = 192), estimated glomerular 
filtration rate < 60 mL/min/1.73 m2 (n = 310), incomplete 
measurement of CIMT (n = 44), and missing clinical vari-
ables (n = 254). Subjects with LDL-C levels ≥ 100 mg/dL 
were also excluded (n = 1,885). In addition, subjects with 
triglycerides (TG) ≥ 400 mg/dL (n = 12), and who took 
fibrates (n = 107), were excluded because hypertriglycer-
idemia can underestimate LDL-C levels [17]. Finally, 845 
subjects (462 men and 383 women) were enrol led in the 
study (Supplementary Fig. 1), which was approved by the 
Institutional Review Board of Yonsei University (IBR 
NO. 4-2017-0288). Due to the retrospective nature of this 
study, the requirement for written informed consent 
was waived.
Clinical variable measurement 
All blood samples were collected from the antecubital 
vein after an 8 to 12 hours overnight fast. Fasting plas-
ma glucose, total cholesterol, TG, HDL-C, and LDL-C 
concentrations were measured enzymatically using a 
747 chemical analyzer (Hitachi, Tokyo, Japan). ApoB and 
ApoA-I were measured using the 7080 chemical analyzer 
(Hitachi). Glycated hemoglobin (HbA1c) was determined 
using high-performance liquid chromatography meth-
od (Variant II, Greencross, Seoul, Korea). Fasting C-pep-
tide levels were measured using a double-antibody ra-
dioimmunoassay (DiaSorin, Stillwater, MN, USA). 
Insulin sensitivity was directly assessed with a short 
insulin tolerance test that measured the rate of plasma 
glucose disappearance (Kitt, %/min) after intravenous 
injection of regular insulin (0.1 U/kg) as described pre-
viously [18-21]. Blood was obtained just prior to insulin 
injection (0 minute), and at 3, 6, 9, 12, and 15 minutes 
after the injection. Plasma glucose concentrations were 
determined immediately after sampling using Beckman 
glucose analyzer II (Beckman Ins., Fullerton, CA, USA) 
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and then Kitt was calculated from the slope of the fall 
in log-transformed plasma glucose concentrations be-
tween 3 and 15 minutes using the following formula: Kitt 
(rate constant for plasma glucose disappearance) = 0.693/
t1/2 × 100 (%/min). We routinely infused 100 mL of 20% 
dextrose solution immediately after the test to avoid any 
potential hypoglycemia.
 
CIMT measurement
Both carotid arteries were scanned using a high-resolu-
tion real-time B-mode ultrasonography with a 10-MHz 
linear transducer (LOGIQ 7, GE, Milwaukee, WI, USA), 
as previously described [21-24]. The CIMT was defined 
as the distance between the lumen-intima and me-
dia-adventitia interfaces [25,26]. CIMT was measured at 
three points on the far wall of 1 cm long section of the 
common carotid artery in the proximity of the carotid 
bulb. The mean value of six measurements from right 
and left carotid arteries were used as the mean CIMT 
[21]. Carotid plaque was defined as focal structures en-
croaching into the arterial lumen of at least 0.5 mm or 
50% of the surrounding intima-media thickness value, 
or a thickness > 1.5 mm [26]. In this study, carotid ath-
erosclerosis was defined as having a carotid plaque or 
diffuse thickening of the carotid wall (mean CIMT ≥ 1.0 
mm) [21,27].
Statistical analyses 
Data are expressed as mean ± standard deviation, me-
dians (interquartile range), or numbers (%). Differenc-
es between two groups were evaluated using a t test or 
Mann-Whitney U test for continuous variables, and by 
a chi-square test for categorical variables. One way anal-
ysis of variance was used to investigate differences in 
variables between ApoB/ApoA-I ratio quartiles. LDL-C 
levels were log-transformed due to the skewed distribu-
tion. Logistic regression analyses were conducted to ex-
amine the correlations between ApoB/ApoA-I ratio and 
the prevalence of carotid atherosclerosis, with and with-
out adjustment for conventional CVD risk factors. The 
strength of the association between the ApoB/ApoA-I 
ratio and mean CIMT was tested by Pearson correlation 
analysis. A variance of inflation factor > 5.0 was used as 
an indicator of multicollinearity. To evaluate the utility 
of the ApoB/ApoA-I ratio as a marker for carotid athero-
sclerosis, we used receiver operating characteristic (ROC) 
curves and calculated the area under the curve (AUC). All 
statistical analyses were performed using SPSS version 
23.0 (IBM Co., Armonk, NY, USA) and STATA software 
version 13.0 (StataCorp LP, College Station, TX, USA). A 
p value of < 0.05 was considered significant.
RESULTS 
Baseline characteristics of all subjects 
Baseline characteristics of the subjects with or without 
carotid atherosclerosis are shown in Table 1. The mean 
age of all subjects was 57.2 years, the mean body mass 
index (BMI) was 24.3 kg/m2, and the median LDL-C lev-
el was 84.0 mg/dL. Subjects with carotid atherosclerosis 
were older, had higher BMIs and systolic blood pressure 
(BP), had experienced diabetes for a longer duration, 
had higher C-peptide levels, and were more insulin re-
sistant. The proportion of men, statin use, and anti-hy-
pertensive drug use were significantly higher among 
subjects with carotid atherosclerosis. HDL-C, LDL-C, 
ApoB, and the ApoB/ApoA-I ratio were also higher in 
subjects with carotid atherosclerosis, while ApoA-I was 
lower. There was no remarkable difference in total cho-
lesterol or TG, use of thiazolidinedione or smoking sta-
tus between groups. 
When the subjects were divided into quartiles based 
on their ApoB/ApoA-I ratios (Table 2), the prevalence 
of carotid atherosclerosis significantly increased across 
quartiles. BMI, proportion of men, TG levels, LDL-C 
levels, and C-peptide increased, while HDL-C and Kitt 
decreased across quartiles. 
Prevalence of carotid atherosclerosis by ApoB/
ApoA-I ratio quartile and LDL-C
Fig. 1 shows the percentage of patients with carotid ath-
erosclerosis by ApoB/ApoA-I ratio quartile and LDL-C 
level. The percentage of patients with carotid athero-
sclerosis (54.5%) was highest in subjects with high ApoB/
ApoA-I ratios (range, 0.71 to 1.59) and high LDL-C levels 
(range, 92 to 100 mg/dL). The ApoB/ApoA-I ratio was 
consistently associated with the prevalence of carotid 
atherosclerosis in T2DM patients with LDL-C level less 
than 100 mg/dL. However, higher LDL-C levels were not 
always associated with a higher prevalence of carotid 
atherosclerosis among them (Fig. 1).
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The risk for carotid atherosclerosis according to 
ApoB/ApoA-I ratio 
The association between the ApoB/ApoA-I ratio and ca-
rotid atherosclerosis was analyzed by logistic regression 
analyses. Univariate logistic regression analyses revealed 
that age, male sex, duration of diabetes, BMI, systolic 
BP, TG, HDL-C, log-transformed LDL-C, C-peptide, 
Kitt, use of anti-hypertensive drugs, use of statins, ApoB, 
ApoA-I, and ApoB/ApoA-I ratio were significant risk 
factors for carotid atherosclerosis (Supplementary Ta-
ble 1). Multivariate logistic regression analyses (Table 3, 
Models 1 to 4) showed that a higher ApoB/ApoA-I ra-
tio, expressed both as quartile and continuous values, 
was significantly associated with a higher risk of carotid 
atherosclerosis, regardless of age, sex, BMI, systolic BP, 
duration of diabetes, use of statins, use of anti-hyperten-
sive drugs, TG, HDL-C, log-transformed LDL-C, or Kitt. 
These factors were all significant based on the univari-
ate logistic regression analyses, along with HbA1c, and 
are known risk factors for atherosclerosis (Model 4). The 
association between the ApoB/ApoA-I ratio and carotid 
atherosclerosis was still significant in males (odds ratio 
Table 1. Clinical characteristics of type 2 diabetes patients according to the prevalence of carotid atherosclerosis 
Characteristic Total
 Carotid atherosclerosisa
p value
No Yes
No. of patients 845 520 (61.7) 325 (38.3)
Age, yr 57.2 ± 8.3 55.1 ± 8.0 60.5 ± 7.6 < 0.001
Male sex 462 (54.7) 268 (51.5) 194 (59.7)  0.021
Body mass index, kg/m2 24.3 ± 3.2 24.1 ± 3.3 24.7 ± 3.0  0.009
SBP, mmHg 133.2 ± 17.3 131.1 ± 17.0 136.6 ± 17.1 < 0.001
DBP, mmHg 85.6 ± 11.4 85.4 ± 11.4 85.8 ± 11.5  0.629
DM duration, yr 8.1 ± 7.3 7.0 ± 6.7 9.8 ± 7.9 < 0.001
Use of statins 163 (19.3) 86 (16.5) 77 (23.7)  0.010
Use of anti-hypertensive drugs 258 (30.5) 139 (26.7) 119 (36.6)  0.002
Use of insulin 95 (11.2) 53 (10.2) 42 (12.9)  0.222
Use of TZD 95 (11.2) 52 (10.0) 43 (13.2)  0.148
Current smokerb 112 (24.2) 70 (26.4) 42 (21.3)  0.207
HbA1c, % 7.9 ± 1.7 7.8 ± 1.8 8.0 ± 1.6  0.107
Fasting glucose, mg/dL 148.3 ± 54.0 148.0 ± 54.8 149.0 ± 52.8  0.813
Total cholesterol, mg/dL 160.2 ± 21.8 159.5 ± 21.9 161.5 ± 21.6  0.188
Triglycerides, mg/dL 132.9 ± 72.1 128.9 ± 72.1 139.3 ± 71.6  0.041
HDL-C, mg/dL 52.3 ± 15.3 53.6 ± 15.4 50.3 ± 14.9  0.002
LDL-C, mg/dL 84.0 (71.0–92.0) 83.0 (70.0–92.0) 86.0 (75.0–92.0)  0.017
ApoB, mg/dL 80.8 ± 19.5 78.5 ± 18.8 84.4 ± 20.1 < 0.001
ApoA-I, mg/dL 138.4 ± 27.8 140.9 ± 28.4 134.4 ± 26.4  0.001
ApoB/ApoA-I ratio 0.61 ± 0.18 0.58 ± 0.17 0.65 ± 0.20 < 0.001
C-peptide, ng/mL 1.8 ± 0.8 1.8 ± 0.8 1.9 ± 0.8  0.029
Kitt, %/min 2.2 ± 1.0 2.3 ± 1.0 2.1 ± 1.0  0.001
Values are presented as number (%), mean ± SD, or median (interquartile range).
SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; TZD, thiazolidinedione; HbA1c, glycated 
hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Apo, apolipoprotein; 
Kitt, rate constant for plasma glucose disappearance.
aCarotid atherosclerosis is defined as carotid intima-media thickness ≥ 1.0 mm or presence of plaque. 
bValue was measured in 462 subjects. 
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[OR], 6.73; 95% confidence interval [CI], 2.30 to 19.71; p 
= 0.001) and females (OR, 12.15; 95% CI, 3.77 to 39.14; p 
< 0.001) when the ApoB/ApoA-I ratio was analyzed as a 
continuous variable in a logistic regression model that 
was fully adjusted for baseline parameters (data not 
shown).
Further, the association between the ApoB/ApoA-I ra-
tio and mean CIMT was analyzed by Pearson correlation 
coefficient (Fig. 2). ApoB/ApoA-I was positively correlat-
ed with mean CIMT in both men (r = 0.09, p = 0.047) and 
women (r = 0.14, p = 0.007). Finally, a significant positive 
correlation was observed in all T2DM subjects (r = 0.12, 
p < 0.001). 
Predictive value of the ApoB/ApoA-I ratio for detect-
ing carotid atherosclerosis
The optimal cutoff value of the ApoB/ApoA-I ratio for 
detecting carotid atherosclerosis was 0.57 in ROC analy-
Table 2. Baseline characteristics of total subjects according to apolipoprotein B/apolipoprotein A-I ratio quartiles 
Variable
Quartile 1
(0.16–0.48) 
Quartile 2
(0.49–0.57)
Quartile 3
(0.58–0.70)
Quartile 4
(0.71–1.59)
p value
No. of patients 211 211 214 209
Mean CIMTa, mm 0.84 ± 0.14 0.89 ± 0.19 0.90 ± 0.19 0.93 ± 0.23 < 0.001
Presence of plaqueb 3 (1.4) 7 (3.3) 6 (2.8) 17 (8.1)  0.001
Carotid atherosclerosisc 54 (25.6) 81 (38.4) 90 (42.1) 100 (47.8) < 0.001
Age, yr 57.6 ± 7.6 57.5 ± 8.3 56.9 ± 8.3 56.6 ± 8.8  0.545
Male sex 89 (42.2) 111 (52.6) 136 (63.6) 126 (60.3) < 0.001
Body mass index, kg/m2 23.5 ± 3.3 24.0 ± 3.0 24.6 ± 2.9 25.1 ± 3.3 < 0.001
SBP, mmHg 132.8 ± 19.0 132.1 ± 17.3 134.1 ± 17.5 133.9 ± 15.0  0.592
DBP, mmHg 85.6 ± 12.1 84.5 ± 11.7 86.2 ± 11.7 85.9 ± 10.1  0.492
DM duration, yr 7.9 ± 7.2 8.7 ± 7.6 7.5 ± 7.1 8.2 ± 7.5  0.454
Use of statins 39 (18.5) 48 (22.7) 41 (19.2) 35 (16.7)  0.472
Use of anti-hypertensive drugs 58 (27.5) 74 (35.1) 65 (30.4) 61 (29.2)  0.976
Use of insulin 32 (15.2) 20 (9.5) 20 (9.3) 23 (11.0)  0.194
Use of TZD 23 (10.9) 30 (14.2) 18 (8.4) 24 (11.5)  0.671
Current smokerd 20 (18.0) 24 (20.3) 32 (27.1) 36 (31.3)  0.009
HbA1c, % 7.9 ± 1.7 7.8 ± 1.6 7.8 ± 1.7 8.1 ± 1.9  0.288
Fasting glucose, mg/dL 146.6 ± 55.7 146.6 ± 48.7 147.4 ± 54.1 152.8 ± 57.3  0.590
Total cholesterol, mg/dL 160.9 ± 24.5 158.3 ± 20.9 159.6 ± 19.2 162.1 ± 22.2  0.305
Triglycerides, mg/dL 99.8 ± 45.2 125.8 ± 70.6 138.8 ± 70.9 167.3 ± 80.3 < 0.001
HDL-C, mg/dL 65.3 ± 16.0 54.5 ± 11.5 47.9 ± 9.8 41.6 ± 12.0 < 0.001
LDL-C, mg/dL 79.0 (65.0–89.0) 81.0 (70.0–91.0) 87.0 (77.0–93.0) 89.0 (81.0–94.0) < 0.001
C-peptide, ng/mL 1.6 ± 0.7 1.7 ± 0.8 1.8 ± 0.8 2.1 ± 1.0 < 0.001
Kitt, %/min 2.3 ± 0.9 2.2 ± 1.0 2.2 ± 1.0 2.0 ± 1.0  0.031
Values are presented as mean ± SD, number (%), or median (interquartile range).
CIMT, carotid intima-media thickness; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; 
TZD, thiazolidinedione; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipo-
protein cholesterol; Kitt, rate constant for plasma glucose disappearance.
aMean CIMT is defined as the mean value of six measurements from right and left carotid arteries.
b Carotid plaque is defined as focal structures encroaching into the arterial lumen of at least 0.5 mm or 50% of the surrounding 
intima-media thickness value, or a thickness > 1.5 mm.
c Carotid atherosclerosis is defined as having a carotid plaque or diffuse thickening of carotid wall (mean CIMT ≥ 1.0 mm).
dValue was measured in 462 subjects. 
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sis of all subjects, with a sensitivity of 58.0% and a spec-
ificity of 55.1%. The cutoff value was 0.60 in men and 
0.56 in women. The AUC of the unadjusted ROC curve 
was 0.61 (95% CI, 0.57 to 0.64; p < 0.001), and the AUC 
of the ROC curve adjusted for age, sex, BMI, systolic 
BP, duration of diabetes, HbA1c, use of statins, use of 
anti-hypertensive drugs, TG, HDL-C, log-transformed 
LDL-C, and Kitt was 0.75 (95% CI, 0.72 to 0.78; p < 0.001) 
(Fig. 3). Using 0.57 as the cut-off value, the OR for carotid 
atherosclerosis was 1.47 (95% CI, 1.01 to 2.15; p = 0.044) 
after adjusting for age, sex, BMI, systolic BP, duration of 
diabetes, HbA1c, use of statins, use of anti-hypertensive 
drugs, TG, HDL-C, log-transformed LDL-C, and Kitt.
DISCUSSION 
This study showed that a high ApoB/ApoA-I ratio was 
significantly associated with carotid atherosclerosis in 
T2DM patients with well-controlled LDL-C concentra-
tions, regardless of conventional CVD risk factors and 
insulin sensitivity. The distribution of ApoB/ApoA-I 
ratios was heterogeneous among the study subjects, de-
spite the controlled LDL-C levels lower than 100 mg/dL. 
In addition, higher LDL-C concentrations were not al-
ways associated with a higher prevalence of carotid ath-
erosclerosis. 
Apos are crucial components of plasma lipoprotein 
particles. ApoB has two major components: ApoB-48, 
which complexes with dietary TG and free cholester-
ol from the gut lumen; and ApoB-100, which is pres-
ent in LDL, intermediate density lipoprotein, and very 
low density lipoprotein (VLDL) particles [28]. The total 
number of ApoB particles indicates the total number of 
atherogenic lipoproteins, because one ApoB molecule is 
present in each of these lipoproteins [9]. ApoA includes 
ApoA-I, the main constituent of HDL, which removes 
excess cholesterol from tissues via lecithin cholester-
ol acyltransferase, and ApoA-II, which inhibits hepatic 
and lipoprotein lipase activity by reducing plasma HDL 
levels [29]. Thus, the ApoB/ApoA-I ratio represents the 
balance between atherogenic and anti-atherogenic par-
ticles, and may improve the prediction of CVD risk.
Several large studies found that the ApoB/ApoA-I ratio 
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Figure 1. Prevalence of carotid atherosclerosis according to 
low density lipoprotein cholesterol (LDL-C) quartile and the 
apolipoprotein (Apo) B/ApoA-I ratio quartile. 
Table 3. Risk for carotid atherosclerosis according to the ApoB/ApoA-I ratio
Quartiles of ApoB/ApoA-I ratio
Continuous vari-
able OR (95% CI)
p valueQuartile 1 
(0.16–0.48)
Quartile 2
(0.49–0.57)
Quartile 3
(0.58–0.70)
Quartile 4
(0.71–1.59)
p for trend
Crude model 1 (reference) 1.81 (1.20–2.75) 2.11 (1.40–3.18) 2.67 (1.77–4.03) < 0.001 9.51 (4.32–20.91) < 0.001
Model 1a 1 (reference) 1.84 (1.18–2.85) 2.21 (1.42–3.43) 3.01 (1.93–4.67) < 0.001 13.67 (5.76–32.49) < 0.001
Model 2b 1 (reference) 1.75 (1.12–2.74) 2.12 (1.36–3.31) 2.76 (1.76–4.34) < 0.001 12.27 (5.01–30.09) < 0.001
Model 3c 1 (reference) 1.57 (0.98–2.53) 1.75 (1.04–2.93) 2.14 (1.21–3.79) 0.014 10.05 (3.26–30.95) < 0.001
Model 4d 1 (reference) 1.57 (0.98–2.53) 1.75 (1.04–2.93) 2.14 (1.21–3.79) 0.014 10.05 (3.26–30.97) < 0.001
Apo, apolipoprotein; OR, odds ratio; CI, confidence interval.
aModel 1 was adjusted for age and sex.
b Model 2 was additionally adjusted for body mass index, systolic blood pressure, duration of diabetes mellitus, glycated hemo-
globin, use of statins, and use of anti-hypertensive drugs.
c Model 3 was additionally adjusted for triglycerides, high density lipoprotein cholesterol, and log-transformed low density li-
poprotein cholesterol
dModel 4 was additionally adjusted for rate of plasma glucose disappearance (Kitt).
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was strongly predictive of MI risk. The AMORIS (Apo-
lipoprotein-related MOrtality RISk) study showed that 
ApoB, ApoA-I, and the ApoB/ApoA-I ratio were stron-
ger predictors of fatal MI risk than total cholesterol or 
TG [14]. The INTERHEART (effect of potentially mod-
ifiable risk factors associated with myocardial infarc-
tion in 52 countries) study, which enrolled patients in 
52 countries, demonstrated that the non-fasting ApoB/
ApoA-I ratio was superior to any other cholesterol ra-
tios for estimating acute MI risk [30]. The PRIME (PRo-
spective Epidemiologic study of Myocardial Infarction) 
study used a prospective cohort that included healthy 
middle-aged men, and also found that the ApoB/ApoA-I 
ratio significantly predicted future CHD and ischemic 
stroke [31]. Finally, a meta-analysis of 23 relevant pro-
spective studies revealed that high ApoB/ApoA-I ratios 
resulted in a 1.8-fold increase in the risk for CHD com-
pared to low ratios [32]. Even in subjects with LDL-C 
levels less than 100 mg/dL, 89.7% of subjects who had 
higher ApoB/ApoA-I ratios (> 0.8) were diagnosed with 
angiographically proven coronary artery disease (CAD), 
and the ApoB/ApoA-I ratio was also positively correlated 
with CAD severity [33]. In addition, both overt CVD and 
subclinical atherosclerosis were significantly associated 
with the ApoB/ApoA-I ratio. An increase in the ApoB/
ApoA-I ratio was associated with an over 50% increased 
risk for coronary artery stenosis and non-calcified 
plaque occurrence [34]. The ApoB/ApoA-I ratio was also 
positively associated with 3-year alterations in CIMT in 
middle-aged men [35]. 
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Figure 2. Correlation between the apolipoprotein (Apo) B/
ApoA-I ratio and mean carotid intima-media thickness 
(CIMT). Black squares for male and white squares for fe-
male. 
Figure 3. Receiver operating characteristic curves of the apo-
lipoprotein (Apo) B/ApoA-I ratio for detecting carotid ath-
erosclerosis. (A) The area under the curve (AUC) of the ApoB/
ApoA-I ratio before adjusting for covariates. (B) The AUC of 
the ApoB/ApoA-I ratio with adjusting for age, sex, body mass 
index, systolic blood pressure, duration of diabetes, glycat-
ed hemoglobin, use of statins, and use of anti-hypertensive 
drugs, triglycerides, high density lipoprotein cholesterol, 
and log-transformed low density lipoprotein cholesterol, 
and the rate of plasma glucose disappearance (Kitt).
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Diabetic dyslipidemia is accompanied by abnormal 
lipid concentrations and altered lipoprotein composi-
tion. Dyslipidemia in T2DM is usually characterized by 
hypertriglyceridemia, reduced HDL-C, and more prev-
alent small dense LDL, while LDL-C concentration is 
normal or slightly increased [16,36]. This dyslipidemia 
was also found in patients with prediabetes who had 
higher insulin resistance and relatively normal glycemic 
indices [37]. Insulin resistance, which plays a key role in 
T2DM development, enhances the hepatic secretion of 
VLDL and regulates ApoB degradation. Increased ApoB 
and TG results in reduced HDL-C, and a consequent in-
crease in the ApoB/ApoA-I ratio [38]. Our results demon-
strated a positive correlation between ApoB/ApoA-I 
ratio quartile and insulin resistance measured by Kitt, 
although the association between the ApoB/ApoA-I ratio 
was still significant after adjustment for Kitt in T2DM 
subjects. However, few studies have been conducted on 
the association between ApoB/ApoA-I ratio and overt 
CVD or subclinical atherosclerosis in diabetic patients. 
One previous population-based cohort study revealed 
that a higher ApoB/ApoA-I ratio was associated with a 
higher risk of cardiovascular mortality, independent 
of non HDL-C in T2DM patients; this association was 
more evident in patients aged over 70 years [39]. Other 
cross-sectional studies showed that the ApoB/ApoA-I 
ratio was positively correlated with CIMT in diabetic 
patients [33,40]. 
The AMORIS and INTERHEART studies suggested 
that an ApoB/ApoA-I ratio of 0.90 for men and 0.80 for 
women were indicative of a high CVD risk, and values 
of less than 0.70 in men and 0.60 in women were con-
sidered to indicate low CVD risk if no other risk factors 
were present [12,14]. The optimal cutoff value for ApoB/
ApoA-I in this study was lower than previously suggest-
ed values obtained in the context of mostly non-dia-
betic subjects. This suggests that smaller alterations in 
lipoprotein composition are associated with CVD in 
patients with diabetes. Incidentally, diabetes is already 
classified as a risk factor for CVD. Another explanation 
is that the ApoB/ApoA-I ratio decreased relative to the 
low concentration of LDL-C.
This study had several limitations. First, we could 
not determine a causal relationship between the ApoB/
ApoA-I ratio and carotid atherosclerosis due to the 
cross-sectional design. Second, there were no data about 
menopausal state leading to changes in lipid profile [41]. 
Third, there were incomplete smoking history and lack 
of data about the anti-platelet agents including aspirin 
or duration of statin treatment, which are known as-
sociated factors with atherosclerosis. Lastly, this study 
was performed at a single center in Korea; hence, it does 
not represent the general diabetic population. How-
ever, in contrast to the previous similar studies [33,40], 
the strength of our study is that we demonstrated the 
correlation between ApoB/Apo-I ratio and carotid ath-
erosclerosis, especially among T2DM patients with 
well-controlled LDL-C.
In conclusion, the ApoB/ApoA-I ratio was inde-
pendently associated with risk of carotid atheroscle-
rosis in T2DM patients whose LDL-C levels were less 
than 100 mg/dL. Lowering LDL-C is undoubtedly an 
effective means of controlling CVD risk, but other lip-
id-modifying strategies may also be important in spe-
cific populations. Although the American College of 
Cardiology Foundation/American Heart Association 
and the National Academy of Clinical Biochemistry do 
not recommend measurement of Apos or any additional 
lipid parameters beyond a standard lipid panel for CVD 
risk assessment [42,43], the ApoB/ApoA-I ratio may be a 
useful marker for CVD risk, especially in T2DM subjects 
with well-controlled LDL-C levels.
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KEY MESSAGE 
1. The apolipoprotein (Apo) B/ApoA-I ratio was 
significantly associated with carotid atheroscle-
rosis in type 2 diabetes mellitus (T2DM) patients 
with low density lipoprotein cholesterol (LDL-C) 
level below 100 mg/dL. 
2. Higher LDL-C levels were not always associated 
with a higher prevalence of carotid atheroscle-
rosis in T2DM patients. 
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Supplementary Table 1. Univariate logistic regression analysis for the presence of carotid atherosclerosis 
Variable Odds ratio (95% CI) p value
Age, yr 1.09 (1.07–1.11) < 0.001
Male sex 1.39 (1.05–1.84)  0.021
Body mass index, kg/m2 1.06 (1.01–1.11)  0.010
SBP, mmHg 1.02 (1.01–1.03) < 0.001
DBP, mmHg 1.00 (0.99–1.02)  0.628
DM duration, yr 1.06 (1.04–1.08) < 0.001
Use of statins 1.57 (1.11–2.21)  0.011
Use of anti-hypertensive drugs (yes) 1.58 (1.18–2.13)  0.002
Use of insulin (yes) 1.31 (0.85–2.01)  0.222
Use of TZD (yes) 1.37 (0.89–2.11)  0.149
HbA1c, % 1.07 (0.99–1.16)  0.108
Fasting glucose, mg/dL 1.00 (0.99–1.00)  0.813
Total cholesterol, mg/dL 1.00 (0.99–1.01)  0.188
Triglycerides, mg/dL 1.01 (1.00–1.04)  0.042
HDL-C, mg/dL 0.99 (0.98–0.99)  0.002
Log-transformed LDL-C, mg/dL 7.71 (1.53–38.75)  0.013
ApoB, mg/dL 1.02 (1.01–1.02) < 0.001
ApoA-I, mg/dL 0.99 (0.98–0.99)  0.001
ApoB/ApoA-I ratio 9.51 (4.32–19.57) < 0.001
C-peptide, ng/mL 1.20 (1.02–1.42) 0.031
Kitt, %/min 0.78 (0.68–0.90) 0.001
CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; TZD, thiazolidinedione; HbA1c, glycated 
hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Apo, apolipoprotein; 
Kitt, rate constant for plasma glucose disappearance.
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3,637 T2DM subjects were assessed for eligibility
(aged 40–75 years)
  34 History of cardiovascular disease 
 192 Abnormal liver function
310 Estimated GFR < 60 mL/min/1.73 m2
  44 Measurement of unilateral CIMT
 254 Missing clinical variables
845 T2DM subjects with LDL < 100 mg/dL
520 Carotid atherosclerosis (–) 325 Carotid atherosclerosis (+)
Supplementary Figure 1. Selection of study subjects. T2DM, 
type 2 diabetes mellitus; GFR, glomerular f iltration rate; 
CIMT, carotid intima-media thickness; LDL, low density 
lipoprotein.
